Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The clinical relevance of Mycobacterial pharmacogenetics.

Tuberculosis (Edinburgh, Scotland) - 1 May 2009

Warren R M, Streicher E M, Gey van Pittius N C, Marais B J, van der Spuy G D, Victor T C, Sirgel F, Donald P R, van Helden P D

Abstract excerpt

Current anti-tuberculosis (anti-TB) drug sensitivity testing methods provide a dichotomous readout: isolates are reported as either drug susceptible or drug resistant. This report demonstrates that rapid molecular methods may provide information concerning both the level of resistance and cross-r...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mycobacterium tuberculosis
Share to Oxidoreductases
Share to Tuberculosis, Multidrug-Resistant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Algorithms

Share to Antitubercular Agents

Share to Catalase

Share to Extensively Drug-Resistant Tuberculosis

Share to Isoniazid

Source

Identifiers

PMID: 19409848
DOI: 10.1016/j.tube.2009.03.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Prepared record publication-19409848-2026-09-05.1. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The clinical relevance of Mycobacterial pharmacogenetics.PMID 19409848Read ↗

Isoniazid-resistant tuberculosis: a cause for concern?Semantic proximity Read ↗

Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis.Semantic proximity Read ↗

Whole genome sequencing of isoniazid monoresistant clinical isolates of Mycobacterium tuberculosis reveals novel genetic polymorphisms.Semantic proximity Read ↗

Genetic polymorphism related to ethambutol outcomes and susceptibility to toxicitySemantic proximity Read ↗

Genetic polymorphisms and adverse reactions to antituberculosis therapySemantic proximity Read ↗

A Nanopore sequencing-based pharmacogenomic panel to personalize tuberculosis drug dosingSemantic proximity Read ↗

A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing.Semantic proximity Read ↗

Mutation profiling for detection of isoniazid resistance in Mycobacterium tuberculosis clinical isolates.Semantic proximity Read ↗

Correlating genetic mutations with isoniazid phenotypic levels of resistance in Mycobacterium tuberculosis isolates from patients with drug-resistant tuberculosis in a high burden setting.Semantic proximity Read ↗

Molecular determinants of drug resistance in tuberculosis.Semantic proximity Read ↗

Identifying isoniazid resistance markers to guide inclusion of high-dose isoniazid in tuberculosis treatment regimensSemantic proximity Read ↗

The rapid diagnosis of isoniazid and rifampicin resistance in Mycobacterium tuberculosis--a molecular story.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.